Supplements vs medicinal products Poland classification is not an academic exercise—it is the decision that dictates your market access timeline, legal liability, and distribution channels. Under Polish law, launching a product as a supplement when it possesses medicinal characteristics can result in immediate market withdrawal, financial penalties, and mandatory reclassification under strict pharmaceutical regulations.
The mistake rarely appears at the notification stage. It surfaces when GIS, during or after reviewing the filing, identifies a composition or presentation issue and refers the question to URPL for a formal opinion—at which point a routine administrative process becomes a substantive classification dispute.
Classification is generally the first legal question a foreign brand should resolve—before formulation is finalized, not after a GIS notification has already been filed. For the wider regulatory picture, see our complete guide on dietary supplements in Poland. This page focuses on the legal tests Polish authorities apply, the priority rule that resolves borderline cases in favor of pharmaceutical regulation, and how to prepare for a classification dispute.
Table of Contents
- Legal Definitions: Dietary Supplement vs. Medicinal Product
- The "Precedence Rule": Article 3a of Polish Pharmaceutical Law
- Key Classification Criteria Used by Polish Authorities
- High-Risk Ingredients and Maximum Daily Dose Thresholds
- How to Handle Borderline Classification Disputes with GIS and URPL
- How CGO Legal Protects Foreign Brands in Product Classification
- FAQ – Supplements vs Medicinal Products Poland
- Explore the Life Sciences & Healthcare Cluster
Legal Definitions: Dietary Supplement vs. Medicinal Product
Polish law defines the two categories through entirely different statutes, built on different regulatory logic.
Under the Act on Food Safety and Nutrition (Ustawa o bezpieczeństwie żywności i żywienia) of 25 August 2006, a dietary supplement is a foodstuff whose purpose is to supplement the normal diet—a concentrated source of vitamins, minerals, or other substances with a nutritional or physiological effect. Its legal identity is nutritional: it supports the body’s ordinary functioning rather than treating a condition.
Under the Pharmaceutical Law (Prawo farmaceutyczne) of 6 September 2001, a medicinal product is a substance or combination of substances presented as having properties for treating or preventing disease, or administered with a view to restoring, correcting, or modifying physiological functions through a pharmacological, immunological, or metabolic action, or to make a medical diagnosis.
The determining question is not what the manufacturer calls the product, but what it does and how it is presented: does it supply nutrients the body already processes as food, or does it exert a targeted, scientifically verifiable pharmacological effect aimed at a disease state? Products that sit close to this line—commonly called borderline products—are where Polish classification disputes concentrate.
Uncertain how your formulation will be classified in Poland?
A pre-market composition and classification audit identifies borderline risks before the GIS notification is filed — the most efficient point in the process to resolve a classification question.
The “Precedence Rule”: Article 3a of Polish Pharmaceutical Law
Poland resolves ambiguous cases through a clear statutory priority rule. Article 3a of the Pharmaceutical Law provides that where a product simultaneously meets the criteria of a medicinal product and the criteria of another type of product—in particular a dietary supplement, cosmetic, or medical device—the provisions of the Pharmaceutical Law apply.
In practice, this means Poland does not treat borderline classification as a coin flip resolved in the manufacturer’s favour. If a product’s composition or presentation is capable of satisfying the medicinal product definition, the stricter pharmaceutical regime takes precedence over the food supplement framework, regardless of how the product is labelled or marketed. This precedence rule is the legal basis GIS relies on when it refers a contested product to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, URPL) during an explanatory proceeding.
For foreign brands, the practical consequence is that a favourable classification in another EU member state does not neutralise this Polish precedence rule — Article 3a applies to how the product is assessed under Polish law, independent of its regulatory status elsewhere.
Key Classification Criteria Used by Polish Authorities
When GIS or URPL assess a borderline product, they generally weigh four categories of evidence, consistent with the classification tests developed in CJEU case law and applied by Polish courts.
- Pharmacological, immunological, or metabolic mode of action. Whether the substance produces a measurable, scientifically demonstrable effect on a physiological function beyond ordinary nutrition — this is the central test distinguishing a medicine from a food.
- Active ingredient composition and dosage levels. Concentration matters as much as identity: a substance that is a permitted nutrient at low doses can cross into pharmacological territory at higher concentrations.
- Presentation, packaging imagery, and implied medical claims. How the product is marketed — capsule design resembling medication, clinical packaging cues, or claims implying disease prevention or treatment — factors into the assessment independent of the actual composition. See our guide on Polish supplement labelling compliance for how claim wording is assessed.
- Target consumer group and route of administration. Products aimed at patients with a specific medical condition, or administered in a manner associated with treatment protocols, weigh toward medicinal classification.
| Assessment Criterion | Dietary Supplement Standard | Medicinal Product Standard | Legal Risk Area |
|---|---|---|---|
| Mode of action | Nutritional or physiological support at normal dietary levels | Demonstrable pharmacological, immunological, or metabolic action | Ingredients with dose-dependent pharmacological effect at supplement-level concentrations |
| Composition / dosage | Within maximum levels set by the Health Minister’s Regulation and GIS Dietary Supplements Team resolutions | Active substance concentration sufficient to produce a therapeutic effect | Exceeding maximum safe levels for vitamins, minerals, or botanicals |
| Presentation and claims | Nutritional / physiological claims authorised under Regulation (EC) 1924/2006 | Claims of disease prevention, treatment, or symptom relief | Marketing language or imagery implying medicinal function |
| Target use and administration | General population, everyday dietary supplementation | Specific patient groups, therapeutic dosing regimens | Positioning toward a named medical condition or clinical use case |
High-Risk Ingredients and Maximum Daily Dose Thresholds
Dosage is often the single most consequential variable in a classification dispute. The Health Minister’s Regulation on the Composition and Labelling of Dietary Supplements sets permitted vitamins, minerals, and their chemical forms, while the GIS Dietary Supplements Team (Zespół do spraw Suplementów Diety) issues resolutions identifying maximum safe levels and substances restricted or prohibited in supplement formulations.
Ingredients that frequently attract scrutiny at higher doses include vitamin D, vitamin B6, melatonin, and a range of botanical extracts with pharmacologically active compounds. A formulation exceeding the accepted safe threshold for one of these substances does not automatically become a medicinal product by operation of law, but it substantially increases the likelihood that GIS will treat the dosage as evidence of a pharmacological rather than nutritional function — particularly where the dose aligns with levels used in registered OTC products containing the same active substance.
Because these thresholds are maintained through resolutions and updated guidance rather than a single static list, a dose that was acceptable in an earlier formulation review is not a guarantee against reassessment. Composition should generally be checked against the current GIS Dietary Supplements Team position before finalising a product intended for the Polish market.
How to Handle Borderline Classification Disputes with GIS and URPL
A classification dispute typically begins when GIS, during or after the notification process, identifies a composition or presentation issue and refers the question to URPL for a formal opinion. This referral is the point at which a routine explanatory proceeding escalates into a substantive classification dispute rather than a documentation query.
Building a defensible evidentiary position
To defend a supplement’s status through this process, the responsible entity generally needs a coordinated evidentiary position, including:
- A scientific dossier demonstrating that the active substances act at nutritional or physiological levels rather than producing a pharmacological effect at the notified dose.
- Comparative dosage analysis against both the permitted supplement thresholds and any registered medicinal products containing the same active substance.
- Documentation of the product’s presentation and marketing materials, showing consistency with nutritional rather than therapeutic positioning — including label wording and health claim compliance.
- Where relevant, evidence of the product’s regulatory history in other EU member states, presented as supporting context rather than as a binding precedent for the Polish authorities.
The goal: removing ambiguity, not arguing preference
Because Article 3a resolves genuine ambiguity in favour of the pharmaceutical regime, the practical goal in a dispute is generally to remove the ambiguity itself — showing clearly that the product does not meet the medicinal product definition — rather than to argue that the supplement classification should simply be preferred where both classifications could apply.
Facing a GIS classification referral to URPL?
Our team supports foreign brands in building the evidentiary position needed to defend supplement status — from scientific dossier preparation to formal representation before URPL.
How CGO Legal Protects Foreign Brands in Product Classification
Our Regulatory & Corporate practice supports foreign manufacturers and brand owners in managing classification risk before and after market entry. The work most often begins at the pre-market stage, where a composition audit is considerably more efficient than defending a reclassification proceeding after the product is already on the Polish market.
We provide pre-market composition and classification audits, assessing dosage levels and active ingredients against Polish thresholds before notification is filed. Where a formal opinion is needed for internal compliance decisions or regulatory submissions, we prepare legal opinions on classification status for the Food Business Operator.
Where a dispute has already been opened, we provide representation before URPL, including responses to classification opinion requests and referrals originating from GIS, and defence in GIS reclassification proceedings, coordinating the scientific and legal evidence needed to preserve the product’s supplement status where the composition supports it.
Considering a market entry for your supplement line in Poland?
A classification and composition audit before notification is the most efficient way to avoid a reclassification proceeding. Our team can review your formulation before you file.
FAQ – Supplements vs Medicinal Products Poland
Can a product classified as a supplement in France or Germany be reclassified as a drug in Poland?
Yes. Classification in another EU member state is relevant context but does not bind Polish authorities. Under Article 3a of the Pharmaceutical Law, a product meeting the medicinal product criteria is subject to Polish pharmaceutical regulation regardless of its status elsewhere in the EU.
What happens if GIS decides my supplement is actually a medicinal product?
GIS can restrict or prohibit further sale of the product as a supplement, generally following a referral to URPL for a classification opinion. Continued marketing as a supplement after such a determination exposes the responsible entity to regulatory and, in serious cases, criminal liability for marketing an unauthorised medicinal product.
Does an opinion from URPL bind GIS during notification?
URPL’s classification opinion is generally treated as the authoritative scientific basis for GIS’s subsequent decision in a borderline case, since URPL is the competent body for assessing pharmacological, immunological, and metabolic action. GIS typically acts on that opinion rather than reaching an independent classification conclusion contrary to it.
Are melatonin or high-dose vitamin D products supplements or drugs in Poland?
It depends on the specific dose and formulation, assessed on a case-by-case basis against current GIS Dietary Supplements Team guidance and registered medicinal product thresholds. Both ingredients are used in supplements at lower doses and in registered medicinal products at higher doses, making dosage review essential before market entry.
Is a favourable classification opinion permanent once obtained?
Generally not indefinitely. Classification is assessed against the current legal and scientific position at the time of review, so a reformulation, updated GIS Dietary Supplements Team guidance, or a change in marketing presentation can prompt a fresh assessment.
Explore the Life Sciences & Healthcare Cluster
This article covers classification of supplements vs medicinal products in Poland. For the wider regulatory framework, entity setup, and market entry overview, start with the main guide; for related operational topics, see the articles below.
- Dietary Supplements in Poland — main regulatory guide
- GIS Notification Guide — step-by-step electronic notification procedure
- Supplement Labelling Rules — mandatory Polish label content and claims standards
- Supplements vs Medicinal Products — current article
- Company Registration in Poland — Sp. z o.o. and branch formation
- VAT Registration in Poland — cross-border VAT compliance
Written by the Regulatory & Corporate Law Practice Team at CGO Legal | Last updated: July 2026
This article provides general information on the classification boundary between dietary supplements and medicinal products in Poland and does not constitute legal advice. Classification outcomes are assessed on a case-by-case basis by GIS and URPL; foreign companies should seek dedicated legal and scientific review of a specific formulation before market entry.
